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Abstract: Methamphetamine is an illicit psychostimulant drug that is linked to a number of diseases
of the nervous system. The downstream biochemical effects of its primary mechanisms are not well
understood, and the objective of this study was to investigate whether untargeted metabolomic
analysis of an in vitro model could generate data relevant to what is already known about this
drug. Rat B50 neuroblastoma cells were treated with 1 mM methamphetamine for 48 h, and
both intracellular and extracellular metabolites were profiled using gas chromatography–mass
spectrometry. Principal component analysis of the data identified 35 metabolites that contributed
most to the difference in metabolite profiles. Of these metabolites, the most notable changes
were in amino acids, with significant increases observed in glutamate, aspartate and methionine,
and decreases in phenylalanine and serine. The data demonstrated that glutamate release and,
subsequently, excitotoxicity and oxidative stress were important in the response of the neuronal cell
to methamphetamine. Following this, the cells appeared to engage amino acid-based mechanisms
to reduce glutamate levels. The potential of untargeted metabolomic analysis has been highlighted,
as it has generated biochemically relevant data and identified pathways significantly affected by
methamphetamine. This combination of technologies has clear uses as a model for the study of
neuronal toxicology.
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1. Introduction
Methamphetamine (CAS 537-46-2), also known as speed or ice, is an illicit psychostimulant drug
that is increasingly being abused around the world. In Australia, it is estimated that 7% of people over
the age of 14 have used methamphetamine at least once [1]. Methamphetamine is highly addictive, and
long-term users develop both dependence and tolerance. It is a proven cause of violent and psychotic
behaviour [2], and is associated with diseases of both the cardiovascular and nervous systems, such as
schizophrenia, Parkinson’s disease and depression [3–6].
The effects associated with methamphetamine use are primarily due to its effect on levels of
monoamine neurotransmitters, including dopamine, noradrenaline and serotonin [7]. Methamphetamine
enters the presynaptic cleft and, subsequently, the presynaptic vesicles, where it causes a change in pH [8,9].
This results in an increased release of monoamines into the cytosol and then the synapse [10]. Of all
monoamines, dopamine plays the key role in methamphetamine-induced toxicity. Elevated dopamine
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levels lead to the formation of dopamine quinones, which bind to cysteine residues, commonly found
in the active sites of enzymes [11], blocking the function of these enzymes [12–14]. It also blocks the
effect of several antioxidants, including glutathione and superoxide dismutase (EC 1.15.1.1) [12,14–16],
leading to a build-up of reactive oxygen species (ROS), which can cause damage to DNA, RNA,
proteins and lipids [17], and neuronal apoptosis [18].
A second key neurotoxic mechanism of methamphetamine is via release of glutamate, the
primary excitatory neurotransmitter in the brain [19]. Briefly, methamphetamine causes the release of
dopamine and the activation of the dopamine D1 receptor, which stimulates the γ-aminobutyric acid
(GABA)-ergic pathway and activates GABA-A receptors. This promotes the release of glutamate from
the neurons, where they trigger excessive activation of the N-methyl-D-aspartate (NMDA) receptor,
causing excitotoxicity [20,21]. The activated NMDA receptor allows for the influx of calcium ions into
the neuron, which leads to the generation of ROS, causing oxidative stress, and nitric oxide, which can
further react with ROS to form the neurotoxin, peroxynitrate [22]. It has also been demonstrated that
glutamate and dopamine can interact to increase this toxicity [23].
It is clear that the combined toxicities of dopamine and glutamate have a substantial impact
on the neuronal cell, however, the resultant effects on the biochemistry of the cell are less
well-understood. Studies have observed changes in the metabolism of different parts of the brain
following methamphetamine use [24,25], meaning that metabolomic analysis, the study of small
molecules produced and consumed during cellular metabolism, may provide the ability to profile
such changes in considerable detail. While there have been extensive studies on gene expression
following methamphetamine treatment [26–28], there have been relatively few studies applying
metabolomic technologies to date. Shima et al. [28] dosed rats with methamphetamine and profiled
metabolites in both urine and plasma, observing that methamphetamine appeared to inhibit glycolysis,
the TCA cycle and β-oxidation of fatty acids. McClay et al. [29] studied changes to brain tissue
in dosed rats, observing an initial increase in energy metabolism, followed by the breakdown of
mitochondria and increased antioxidants. Zaitsu et al. [30] profiled metabolites in the urine and
plasma of methamphetamine-addicted rats, and identified changes, primarily in fatty acids, while
Choi et al. [31] observed similar changes in the hair of a rat self-administration model. Zheng et al. [32]
conducted a dose escalation study on rats and observed an increased TCA cycle and lipid metabolism,
along with an increased stimulation and decreased inhibition of the nervous system.
As seen in the above studies, the application of metabolomics to toxicological studies has largely been
through animal studies. Within the toxicology community, there continues to be considerable emphasis
on identifying alternative approaches that avoid the use of animals. In vitro models for assessing toxicity
using metabolomics have been developed, but have primarily focused on hepatotoxicity [33,34]. Very few
studies have used this approach for the assessment of neurotoxicity [35]. We have recently demonstrated
that gas chromatography–mass spectrometry (GC–MS) metabolomic analysis could be used to generate
meaningful biochemical data about the effects of a high dose of insecticides on a continuous cell line, the
rat B50 neuroblastoma [36]. The aim of this study was therefore to determine whether this same model
could be applied to the study of methamphetamine toxicity, and to generate biologically relevant data.
2. Results
Cell viability following treatment with methamphetamine at different doses was assessed using
cell counting with Trypan blue exclusion (Figure 1). Treatment with 1 mM methamphetamine for 48 h
caused cell viability to drop to 61.3 ± 4.4%, while treatment with 10 and 100 mM caused decreases
to 79.1 ± 3.2% and 74.1 ± 4.3%, respectively. Lower doses caused decreases in viability of less than
10%. As more than 50% of cells remained viable at 1 mM methamphetamine, this dose was used for
subsequent experimentation.
Principal component analysis of the intracellular metabolite profiles of methamphetamine-treated
cells (Figure 2) showed a clear distinction between control and treated cells, with the majority of
the variance between the two groups explained by PC-1 (53%). The PCA of the medium taken from
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these cells (extracellular) (Figure 3) also showed two distinct groups, with PC-1 again explaining the
majority of the variance (67%). PCA loadings identified 35 metabolites, which contributed most to the
variance observed between methamphetamine-treated and untreated cells (X-loading > 0.1), and 49
metabolites in the corresponding extracellular samples. Further analysis focused on the 35 metabolites
identified in the intracellular samples (Table 1), allowing for the comparison of relative intracellular
and extracellular changes.
Table 1. Metabolites identified by PCA as contributing most to the variance between untreated and
methamphetamine-treated rat B50 neuroblastoma cells, and the fold change observed in the treated
cells and medium (n = 9), compared to the untreated ones (n = 9). ‘-’ indicates no change. Statistical
significance was determined using Student’s t-test and is indicated as * p < 0.05; ** p < 0.01.
Metabolite Cells (Fold Change) Medium (Fold Change)
Amino Acids
N-Acetylglutamate 4.7 ** 1.4 *
L-Alanine 0.8 1.4 **
L-Arginine 1.1 1.3 *
L-Aspartate 8.0 ** 2.6 **
L-Glutamate 3.3 ** 2.1 **
Glycine - 1.1
L-Isoleucine 0.9 1.7 **
L-Leucine 1.4 1.1
L-Methionine 3.5 ** 2.5 **
L-Phenylalanine 0.5 ** 1.9 **
L-Proline 0.7 ** 1.1
Pyroglutamate 1.1 1.7 **
L-Serine 0.3 ** 3.0 **
L-Threonine 0.9 1.3 *
L-Tryptophan - 1.7 **
L-Tyrosine - 1.7 **




Galactose 1.1 ** 1.2 **
Glucose 2.4 -
Mannose 0.6 -
Unidentified carbohydrate 1 1.6 ** 1.2
Unidentified carbohydrate 2 1.3 0.9
Unidentified carbohydrate 3 1.3 1.1
Other metabolites
Cholesterol 0.6 ** not detected
Erythronate 0.9 1.1
Fumarate 2.1 ** 1.1
GABA 0.2 ** not detected
Glycerol 0.2 ** -
Hexadecanoate - 1.1
myo-Inositol 1.3 ** -
Octadecanoate 1.3 * 0.8
Succinate 1.6 * -
Tryptamine 2.1 ** not detected
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Figure 1. Cell viability of rat B50 neuroblastoma cells untreated or treated for 48 h with 
methamphetamine at 100 nM, 1 μM, 10 μM, 100 μM and 1 mM, determined using cell count with 
Trypan Blue exclusion. n = 3 for all conditions and error bars are SEM. 
 
Figure 2. Principal component analysis scores plot of metabolite profiles generated by GC–MS 
analysis of rat B50 neuroblastoma cells (intracellular samples) untreated (C) (n = 9) or treated with 1 
mM methamphetamine for 48 h (T) (n = 9). 
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of culture medium (extracellular samples) from rat B50 neuroblastoma cells untreated (C) (n = 9) or
treated with 1 mM methamphetamine for 48 h (T) (n = 9).
2.1. Amino Acids
The main overall trend observed a 1.8-fold intracellular increase in amino acid levels
in methamphetamine-treated cells, and a 1.6-fold extracellular increase. Six amino acids showed
significant changes in both intracellular and extracellular samples. Of particular interest is the 3.3-fold
intracellular increase in glutamate, coupled with a 2.1-fold extracellular increase (both p < 0.01).
N-acetylglutamate levels also showed a 4.7-fold intracellular increase (p < 0.01) and a 1.4-fold
extracellular increase (p < 0.05), a further indicator of increased glutamate levels. Aspartate levels
showed an 8.0-fold intracellular increase and a 2.6-fold extracellular increase (both p < 0.01), while
methionine showe a 3.5-fold intrac llular increase and a 2.5-fold extracellular increase (both p < 0.01).
A 2.3-fold intrac llular decrease (p < 0.01) was observed in levels of phenylal nine, while serine levels
showed a 3.1-fold intracellular decrease (p < 0.01) and a 3.0-fold extracellular increase (p < 0.01).
Intracellular proline levels decreased 1.4-fold (p < 0.01), and a non-significant change was observed
in alanine levels, with a 1.3-fold intracellular decrease, although a 1.4-fold extracellular increase was
significant (p < 0.01). Intracellular leucine levels did increase 1.4-fold, although this was not significant.
A number of other amino acids showed significant extracellular increases in methamphetamine-treated
cells, namely, arginine, isoleucine, threonine, tryptophan, tyrosine and valine (all p < 0.01, except
arginine and threonine, where p < 0.05).
2.2. Other Metabolites
Several othe metabolites w re also affected by meth mphet mine t atment. Intracellular
γ-amino-bu yric acid (GABA) decreased 3.4-fold, which was a significant difference (p < 0.01), but
it was not detected in the medium. The only significant changes observed in carbohydrates were a
1.1-fold intracellular increase in galactose, coupled with a 1.2-fold extracellular increase, and a 1.6-fold
intracellular increase in an unidentified carbohydrate (all p < 0.01). Other notable, non-significant,
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intracellular changes observed were in glucose, which was 2.4-fold higher, and mannose, which
was 1.6-fold lower (both p > 0.05). Metabolites that showed intracellular increases include fumarate
(2.1-fold, p < 0.01), succinate (1.6-fold, p < 0.05) and pyroglutamate (1.7-fold, p < 0.01). A significant
intracellular increase in octadecanoate (1.3-fold, p < 0.05) was observed, along with a non-significant
extracellular decrease (1.2-fold). Intracellular cholesterol levels decreased 1.8-fold (p < 0.01) and
intracellular glycerol levels also decreased (4.2-fold, p < 0.01). Tryptamine, a neuromodulator that
promotes the release of serotonin from neurons, showed a 2.1-fold intracellular increase (p < 0.01).
3. Discussion
This study has successfully observed differences in the intracellular metabolite profile of cultured
neuronal B50 cells and, as can be seen below, associated specific differences with known effects of
methamphetamine exposure. Untargeted metabolomic analysis detected hundreds of individual
metabolite features and PCA showed separate grouping of the treatment and control. These data,
comprising metabolites from a range of classes, highlight the suitability of combining cultured cells
with metabolomics for the monitoring of cellular responses to toxic chemical exposure. This has clear
potential for future toxicology testing practices, particularly given the increasing interest in using
human-derived cell lines [37]. Such an approach, for the prediction of toxic effects on biochemical
pathways, is not only essential for enhancing our understanding of toxicology, but is also essential for
the reduction of the use of animals in toxic chemical testing. As previously advocated, a ‘whole of cell’
metabolomic approach has benefits over individual biomarkers derived from animal studies, because
it allows changes across entire biochemical pathways to be profiled, giving a more complete picture of
the effects of toxins [36]. Future studies should compare the metabolic effect of methamphetamine on
a human neuronal cell line with that on the rat B50 neuronal cell line.
The changes profiled in the metabolites of cells exposed to methamphetamine are interpretable in
the context of the known biochemical effects of methamphetamine exposure, as demonstrated below,
with a focus on amino acids and energy metabolism.
3.1. Amino Acids
Significant increases were observed in both intracellular and extracellular levels of glutamate.
Methamphetamine stimulates the release of glutamate via dopamine and GABA [19], which causes
the activation of NMDA receptors and, subsequently, excitotoxicity. This leads to oxidative stress and
further damage to the neuronal cell [20,21]. In terms of the metabolites identified as important in this
study, it is clear that glutamate had a substantial influence on the cells. Increased glutamate levels
were previously observed in a rat model of methamphetamine administration [32]. The mechanism
described would have also contributed to an decrease observed in levels of the neurotransmitter, GABA.
GABA is oxidised to both succinate and glutamate, both of which showed a significant intracellular
increase. The oxidation of GABA primarily occurs when glucose is limited, as succinate can provide
an alternative carbon source, suggesting that glucose transport was interrupted. The importance of
GABA in response to methamphetamine has recently been reviewed by Chiamulera et al. [38].
The expected excitotoxic effect, and the cell’s need for protection against it, appears to have driven
other changes observed in the amino acid levels. The significant increase in aspartate levels suggests
that the cells may be attempting to reduce glutamate and the associated excitotoxicity via aspartate
transaminase (AST), which converts glutamate into α-ketoglutarate, while producing aspartate from
oxaloacetate. Increased aspartate levels were also observed in the aforementioned rat study [32].
Serine has been demonstrated to have both antioxidant and neuroprotective effects [39,40], and thus
may have been produced by the cell in the early response to exposure and then transported out in a
sampling time of 48 h. Methionine, which is also known to have antioxidant properties [41], showed
both intracellular and extracellular increases.
In terms of these significant changes in amino acid levels, the general mechanism suggested by the
metabolomic data is that methamphetamine treatment causes the production and release of glutamate,
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which the cell attempts to balance by increasing the production of aspartate via AST. The oxidative
stress caused by glutamate stimulates the production of methionine and serine. The intracellular
decrease in serine suggests that it is produced during the initial stages of methamphetamine exposure,
and methionine is produced later.
3.2. Energy Metabolism
Observed changes in carbohydrate levels were less pronounced than in amino acids. The high
levels of glucose present in DMEM (4.5 g/L) could mask changes in carbohydrate metabolism.
Glucose is transported into neuronal cells via the specific GLUT3 transporter [42], and recent work
has shown that methamphetamine can inhibit GLUT3, preventing the transport of glucose into
the neuron, especially at high doses [43]. It was therefore expected that glucose levels would be
depleted within the cells. However, it is likely that by the time cellular metabolism was quenched
at 48 h, methamphetamine had been degraded, allowing for the resumption of glucose transport via
GLUT3. The inclusion of additional time points in future studies would help to clarify the effect on
glucose levels.
Methamphetamine is known to trigger the production of reactive oxygen species, via dopamine
quinone production [44], which causes damage within the cell. This damage may affect the ability of the
cell to utilise the glucose that it transports in after an extended period of exposure to methamphetamine,
further contributing to build-up within the cell. The observed intracellular increases in fumarate and
succinate also indicate that aerobic metabolism was affected by treatment. Pyroglutamate is an
uncommon amino acid that can be produced during oxidative stress [45] and has been shown to
interfere with energy production in a rat cerebral cortex [46].
Previous studies on the biochemical effects of methamphetamine treatment have indicated that
energy metabolism is one of the most commonly affected pathways. Shima et al. [28] observed that
methamphetamine appears to inhibit glycolysis, the TCA cycle and β-oxidation of fatty acids in
rats 24 h after exposure. By 96 h, the urine and plasma metabolite profiles of control and treated
rats were indistinguishable, indicating that changes in energy metabolism likely occur during the
period immediately following exposure. McClay et al. [29] studied mouse brain tissue 1 h after
methamphetamine exposure, either once or daily for up to 5 days. This study found that an acute dose
perturbed energy metabolism, including the TCA cycle, while repeated doses led to mitochondrial
damage, disrupting energy generation. Zheng et al. [32] observed energy metabolism increases
corresponding to escalating doses in rats, specifically, increases in the TCA cycle and lipid metabolism.
Samples in this study were collected only 1 h after administration and thus reflect an acute effect of
the drug.
The present data indicate that carbohydrate metabolism was affected by methamphetamine
treatment, although the specific pathways involved are unclear. This highlights an important
consideration in metabolomic studies. The time of the sampling, as a single time point, can only
provide a snapshot of the biochemical status of the cell. In order to fully understand the effect of
methamphetamine treatment on carbohydrate metabolism in neuronal cells, a time course should be
conducted over the course of treatment. Further refinements to the approach would include the use of
pooled quality control samples, which are routinely employed in metabolomic studies, and would
allow the biological variance within the dataset to be fully separated from the instrumental variance.
3.3. Conclusions
Metabolite profiles of methamphetamine-treated cells and corresponding medium samples
showed changes that fit with what is known about the effects of this drug on neuronal cells.
Most notably, the data demonstrated that glutamate release and subsequent excitotoxicity and oxidative
stress constituted a major part of the response of the neuronal cell to methamphetamine. Following
this, the cells appeared to engage a number of amino acid-based mechanisms to attempt to reduce
glutamate levels. This likely included the well-characterized use of aspartate transaminase to convert
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glutamate into aspartate, leading to a marked increase in aspartate levels. The data also indicate
that two mechanisms not previously linked to methamphetamine treatment may be involved in the
response of the cells, namely the production of serine and methionine as antioxidants. Expected
changes to energy metabolism were not clear from the data, possibly because these changes occur over
a shorter timeframe than the 48-hour timeframe used in the current study.
Untargeted metabolomic analysis identified multiple biochemical pathways in the B50 neuroblastoma
cell that were affected by methamphetamine treatment. The data generated were biochemically relevant
and show the potential of this technology in studying the response of cells to drugs and other toxins.
By expanding the use of metabolomic technologies in toxicology analysis, it will be possible to identify
links between biochemical pathways and highlight pathways not previously known to be involved in
the cellular response, which may provide new targets for the development of protective therapies.
4. Materials and Methods
4.1. Chemicals
All chemicals were purchased from Sigma Aldrich (Sydney, Australia) in the highest purity
available, unless otherwise stated. Solvents were purchased from LabScan (Seacliff, Australia) in the
highest purity available.
4.2. Cell Culture
B50 rat neuroblastoma cells were obtained from the European Cell Culture Association via
Sigma Aldrich. Cells were maintained at 37 ◦C and 5% CO2 in Dulbecco’s modified Eagle medium
(DMEM) and supplemented with 1% glutamine, 1% penicillin/streptomycin and 5% fetal calf serum
(heat-treated at 56 ◦C for 2 h). Passages between 4 and 6 were used for experimentation. Prior to
treatment, cells were cultured in 6-well plates until 75–85% confluent. Methamphetamine exposure
was conducted in triplicate on cells from three consecutive passages (n = 9 for each condition). For each
of the treatments, 3 plates were exposed to 1 mM methamphetamine (in sterile water) for 48 h, while
another 3 were left untreated as control (sterile water vehicle added).
In order to investigate the biochemical effects of methamphetamine exposure, the dose of
methamphetamine used needed to leave a sufficient number of cells alive to provide a metabolism
that could be profiled. A 1 mM dose of methamphetamine has previously been shown to decrease
cell viability by up to 50% [47,48] and similar doses have been used in other in vitro studies of
methamphetamine toxicity, with exposures from 24 to 48 h [49,50]. For this reason, cells were exposed
in triplicate to methamphetamine at the following doses for 48 h: 100 nM, 1 µM, 10 µM, 100 µM and
1 mM. Cell viability was determined using Trypan blue staining. The medium was removed and
500 µL of trypsin (EC 3.4.21.4) was added. The plates were returned to the incubator for 5 min and
then 2 mL of DMEM was added to terminate trypsinization. A 1 mL aliquot of the cell suspension
was centrifuged at 4500× g for 5 min, and the supernatant was discarded. The resultant pellet was
resuspended in 1 mL of PBS. The cell suspension was mixed at a ratio of 1:1 with 0.4% Trypan Blue
and counted using an Improved Neubauer Haemocytometer (Sigma Aldrich) and an Olympus CKX41
inverted light microscope (Olympus, Mt. Waverley, Australia). Cells were counted within the four
corner squares; cells falling on the centre borders were counted, but those outside the borders were
excluded. An average of two counts was used to represent a mean cell count for that plate. The viable
(unstained) and non-viable (blue-stained) cells were counted separately and used to estimate viability.
4.3. Sample Preparation
Optimization of the method indicated that a single well on a 6-well plate did not contain sufficient
cells (approximately 2 × 106 cells per well) to yield adequate metabolites for reproducible GC–MS
profiling (data not shown). For this reason, 5 wells from each 6-well plate were harvested together,
representing approximately 107 cells.
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After 48 h incubation, the plates were removed from the incubator and placed on ice. A 40 µL
aliquot of the culture medium was removed, and 5 wells were combined in a 1.5 mL tube that was
immediately placed on dry ice. The remaining medium was removed from each well and the cells
were carefully washed with 1 mL of phosphate-buffered saline (PBS) solution at 4 ◦C. This wash was
discarded and 100 µL of PBS was added to each well. Recent studies [51] have shown that cold PBS is
the best solution for quenching metabolism in cultured mammalian cells. The cells from 5 wells of each
6-well plate were harvested using a 16 mm cell scraper and immediately placed on dry ice. Both the
cell and medium samples were freeze-dried using a Freezone 2.5 Plus (Labconco, Kansas City, MI,
USA). The remaining well on each 6-well plate was used to provide a mean cell count using Trypan
blue staining, as described above.
Following freeze-drying, samples were centrifuged at 5000× g for 5 min. Metabolites were
extracted using 500 µL methanol containing 13C6-sorbitol, as an internal standard, at a concentration
of 3 µg/mL. Methanol extraction has been demonstrated to be the optimal solvent for the extraction
of adherent cells for GC–MS analysis [29]. Solutions were transferred to fresh tubes and lysed in a
Procellys tissue lyser (Bertin Corporation, Rockville, MD, USA) at 6500 rpm for 2 × 20 s. Samples were
subsequently centrifuged at 13,200× g for 5 min, and 400 µL of the supernatant was transferred
to a fresh tube. The volume was reduced using a Concentrator Plus rotary vacuum concentration
(Eppendorf South Pacific, North Ryde, Australia), and 250 µL water was added to facilitate freezing at
−80 ◦C. Once frozen, samples were freeze-dried.
Dried samples were derivatised according an established protocol [52,53]. Methoxyamine
(20 mg/mL in pyridine) was added (20 µL), and the samples were mixed in a Thermomixer Comfort
(Eppendorf South Pacific) at 1200 rpm for 90 min at 30 ◦C. The samples were centrifuged at 13,200× g
for 1 min, and 40 µL of N-Methyl-N-(trimethylsilyl) trifluoroacetamide (MSTFA) was added. The
samples were returned to the thermomixer and mixed at 300 rpm for 30 min at 37 ◦C. Once derivatised,
the samples were transferred to 2 mL GC vials, and 5 µL of alkanes (C10-C36, 0.625 mg/mL in hexane)
was added to allow for the calculation of a Kovat’s index.
4.4. Analysis
Samples were analysed using an Agilent 6890 gas chromatograph, with an Agilent 7863
autosampler, coupled with an Agilent 5973N mass spectrometer (Agilent Technologies Australia,
Mulgrave, Australia). Helium was used as a carrier gas, and the column was an Agilent Factor Four
VF-5 ms fused silica capillary column (dimensions 30 m × ID = 0.25 mm × Df = 0.25 µm + 10 m
EZ-Guard). Using an established method [52,53], the temperature of the inlet was set to 230 ◦C, and
the initial oven temperature was set to 70 ◦C. Temperature was increased at 1 ◦C/min for 6 min and
then ramped up by 5.63 ◦C/min to a final temperature of 330 ◦C, and held for 10 min. The transfer
line to the mass spectrometer was set to 330 ◦C and the ion source, to 230 ◦C and 70 eV, with a solvent
delay of 8.0 min. The detector was set to full scan, monitoring a mass range of m/z 45–600 at 1 scan
per second. GC–MS data were deconvoluted using AnalyzerPro v. 2.7.0 (SpectralWorks, Runcorn, UK),
normalized to viable cell count and referenced against an in-house target component library, which
comprised both mass spectrum and retention index.
4.5. Statistical Analysis
The results of GC–MS analysis were exported to The Unscrambler X v. 10.1 (CAMO Software,
Oslo, Norway), and log10 was transformed. Principal component analysis (PCA) was undertaken,
using a non-linear iterative partial least squares algorithm, cross validation and no rotation. Data from
PCA were used to identify those metabolites that contributed the most to the variance observed
between methamphetamine-treated cells and control. Subsequent statistical analysis was undertaken
using SPSS Statistics v. 21 (IBM Corporation, Armonk, NY, USA). Metabolite levels in control and
treated samples were compared using an unpaired Student’s t-test, assuming equal variance, coupled
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with the Benjamini-Hochberg false discovery rate correction. All error bars represent the standard
error of the mean (SEM).
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